Top FDA Official Appointed By Trump Admin Departs After Three Months
Newsweek6 days
Prasad's departure represents a victory against regulatory overreach that threatened patient access to life-saving treatments. His decision to halt Elevidys shipments ignored desperate families fighting Duchenne muscular dystrophy and demonstrated dangerous government interference in medical decisions. The Wall Street Journal correctly identified this as regulatory "mugging" that chills pharmaceutical innovation.
Prasad'sThe resignation showsexposes howdangerous pharmaceutical lobbying and political pressureinterference canin underminescientific legitimatedecision-making safety concerns at the FDA. HisPrasad evidence-basedwas approachforced toout drugafter approvalsmaking andevidence-based willingnesssafety todecisions questionabout treatmentsa withgene questionabletherapy efficacylinked representedto exactlypatient thedeaths, kinddemonstrating ofhow scientificindustry rigorlobbying theand agencyactivist needs.pressure Thecan coordinatedoverride attacklegitimate againstregulatory himconcerns prioritizedabout industrydrug profits over patient safety.
Prasad's resignation shows how pharmaceutical lobbying and political pressure can undermine legitimate safety concerns at the FDA. His evidence-based approach to drug approvals and willingness to question treatments with questionable efficacy represented exactly the kind of scientific rigor the agency needs. The coordinated attack against him prioritized industry profits over patient safety.